Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.33 |
| ▸ | DYRK2 | Q92630 | 5/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.33 |
| ▸ | CDK2 | P24941 | 4/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.33 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.33 |
| ▸ | CDK9 | P50750 | 2/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1161134 | 1.00 | MET (0.62) | METDYRK1ADYRK2CCNA2CDK2 | |
| SCHEMBL1161520 | 1.00 | MET (0.62) | METDYRK1ADYRK2CCNA2CDK2 | |
| SCHEMBL1161745 | 0.89 | MET (0.50) | METDYRK1ADYRK2CCNA2CDK2 | |
| SCHEMBL1163296 | 0.89 | MET (0.52) | METDYRK1ADYRK2CCNA2CDK2 | |
| SCHEMBL1161246 | 0.80 | MET (0.62) | METDYRK1ADYRK2CCNA2CDK2 | |
| SCHEMBL1161467 | 0.80 | MET (0.62) | METDYRK1ADYRK2CCNA2CDK2 | |
| SCHEMBL1161266 | 0.80 | MET (0.62) | METDYRK1ADYRK2CCNA2CDK2 | |
| SCHEMBL1163555 | 0.80 | MET (0.67) | MET | |
| SCHEMBL1161342 | 0.79 | MET (0.62) | MET | |
| SCHEMBL1192218 | 0.79 | MET (0.41) | METDYRK1ADYRK2CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462143-B1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES AS C-MET TYROSINE KINASE MODULATORS | NOVARTIS AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8389526-B2 | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives | NOVARTIS AG (CH) | 2013-03-05 | — | — | US | disclosed |
| US-8389526-B2 | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives | NOVARTIS AG (CH) | 2013-03-05 | — | — | US | disclosed |
| US-8389526-B2 | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives | NOVARTIS AG (CH) | 2013-03-05 | — | — | US | disclosed |
| EP-2462143-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES AS C-MET TYROSINE KINASE MODULATORS | Novartis AG (CH) | 2012-06-13 | — | — | EP | disclosed |
| US-20110039831-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES | NOVARTIS AG (CH) | 2011-02-17 | — | — | US | disclosed |
| US-20110039831-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES | NOVARTIS AG (CH) | 2011-02-17 | — | — | US | disclosed |
| US-20110039831-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES | NOVARTIS AG (CH) | 2011-02-17 | — | — | US | disclosed |
| WO-2011015652-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES AS C-MET TYROSINE KINASE MODULATORS | NOVARTIS AG (CH) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039831-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES | MET, ERBB2, ABL1 | MET 1/4885DYRK1A 292/4885DYRK2 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.